Published on 09/12/2025

E&L Risk Assessment Playbook: Linking Materials, Contact, and Patient Exposure

Extractables and leachables (E&L) testing is a critical aspect of pharmaceuticals and medical device manufacturing. It ensures that the materials used in the manufacturing process do not adversely affect product safety and efficacy. This playbook serves as a comprehensive guide for a robust E&L risk assessment, linking materials, contact, and patient exposure. This article is particularly focused on US FDA regulations, EU GMP Annex 1, and the guidelines from various regulatory bodies.

1. Introduction to E&L Risk Assessment

The increasing complexity of pharmaceutical products, especially with the introduction of single-use systems, necessitates a thorough understanding of E&L risk assessment methodologies. Extractables refer to the substances that can be extracted from packaging or materials upon exposure to a solvent, while leachables are those that migrate into a specific solution or product during storage or use. Understanding these concepts is crucial for identifying potential risks associated with container closure integrity (CCI) and overall product safety.

This article outlines a step-by-step process for conducting E&L risk assessments, focusing on the analytical evaluation threshold (AET) and dose-based threshold (DBT) calculations. By integrating this knowledge with current regulatory requirements, professionals can ensure compliance with both US and EU standards.

2. Step 1: Identify Materials and Components

The first step in any E&L risk assessment is to identify all materials and components that will come into direct or indirect contact with the drug product. This includes:

• Container closure systems (CCS)
• Single-use systems
• Processing equipment materials
• Packaging materials

Each identified material must be documented to facilitate a thorough evaluation of potential chemical interactions. Regulatory frameworks such as FDA and EMA offer guidelines on acceptable risk management practices.

3. Step 2: Conduct Initial Risk Assessment

Once materials are identified, an initial risk assessment must be performed. This involves assessing the materials based on their chemical composition, the likelihood of extractables and leachables migrating into the pharmaceutical formulation, and the potential toxicity of these compounds. Considerations should include:

• Material compatibility with the drug product
• Environmental conditions (e.g., temperature, pH)
• Duration of contact between the drug product and the materials
• Previous data on extractables and leachables from similar systems

This initial assessment will help categorize materials into different risk profiles, guiding the subsequent testing and evaluation processes.

4. Step 3: Determine AET and DBT

Calculating the analytical evaluation threshold (AET) and the dose-based threshold (DBT) is essential for establishing acceptable limits for extractables and leachables. The AET is the lowest concentration at which the sum of toxicologically relevant leachables in a product will cause concern based on current toxicological data.

To calculate AET, consider the following formula:

AET = (Toxicological Limit) / (Daily Intake)

For DBT, evaluation should reflect the daily dose and the associated safety limits based on toxicological assessments. The DBT calculation can be summarized as:

DBT = (Toxicological Limit) x (Body Weight) / (Biological Availability)

Carefully documenting these calculations ensures compliance with regulatory expectations and provides a defensible risk management strategy.

5. Step 4: Performing Extractables and Leachables Testing

With established AET and DBT values, the next step involves performing E&L testing to quantify the leachables present in the pharmaceutical formulation. This should be executed according to validated analytical methods such as:

• Gas Chromatography-Mass Spectrometry (GC-MS)
• High-Performance Liquid Chromatography (HPLC)
• Inductively Coupled Plasma Mass Spectrometry (ICP-MS)

Testing can be conducted under worst-case scenarios to ensure that maximum levels of migration are evaluated. This may include stress testing the materials under elevated temperature and/or extended contact time with the drug product.

6. Step 5: Evaluate Results Against Established Thresholds

Once E&L testing is completed, results must be systematically compared to the previously established AET and DBT thresholds. If levels exceed these thresholds, further work is required to understand the source, potential toxicity, and impact of the leachables detected. Thorough documentation of the results and comparisons with established toxicological data will further substantiate compliance with guidance such as the PQRI guidelines.

In cases where levels exceed acceptable limits, strategies for material substitution or modification may be necessary to ensure patient safety and regulatory compliance.

7. Step 6: Document Findings and Establish Controls

Documenting the entire E&L risk assessment process, findings, and resulting action plans is critical. Quality Management Systems (QMS) must integrate these findings to assure ongoing compliance and improve processes. This documentation should include:

• Comprehensive reports of risk assessments
• Analytical method validation reports
• Control measures implemented based on findings

This structured approach ensures not only compliance with EU GMP Annex 1 but also alignment with industry best practices.

8. Step 7: Training and Continuous Improvement

Finally, to ensure the sustained effectiveness of the E&L risk assessment program, training sessions should be conducted for all relevant personnel, emphasizing the importance of compliance and vigilance in monitoring E&L risks. Training methodologies should include:

• Regular updates on regulatory expectations and industry advancements
• Workshops focusing on advanced analytical techniques
• Case studies demonstrating the practical application of E&L risk assessments

Encouraging a culture of continuous improvement and compliance helps the organization remain proactive in identifying potential E&L risks and addressing them in a timely manner.

Conclusion

In conclusion, conducting an effective E&L risk assessment is paramount for ensuring patient safety and product integrity. By following the structured steps outlined in this playbook and ensuring thorough documentation, pharmaceutical professionals can confidently navigate the complexities of E&L testing, all while adhering to the regulatory standards set forth by organizations such as the FDA, EMA, and PIC/S. As the industry evolves, staying informed and compliant with the latest practices will be essential for success in maintaining the safety and efficacy of pharmaceutical products.